Payment overview · 2025
General Payments
$348.77
16 reported records · 10 companies
Healthcare provider profile · identity verified
Richard Dwight Meadows, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BECKLEY, WV · NPI 1164874798
Verified facts
What the public records show
CMS Open Payments records show Richard Dwight Meadows, D.O. received $348.77 in general payments during 2025 across 16 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 39.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $138.93 | 39.8% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.75 | 10.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.57 | 8.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.38 | 7.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.96 | 6.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.69 | 6.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.01 | 5.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.34 | 5.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.36 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.78 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $348.77 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $138.93 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 145 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
145 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 569 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 110 |
| Lisinopril | Lisinopril | 362 | 92 |
| Gabapentin | Gabapentin | 336 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 334 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 299 | 87 |
| Omeprazole | Omeprazole | 286 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 83 |
| Potassium Chloride | Potassium Chloride | 280 | 78 |
| Montelukast Sodium | Montelukast Sodium | 276 | 66 |
| Lorazepam | Lorazepam | 259 | 55 |
| Famotidine | Famotidine | 252 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 246 | 105 |
| Tramadol Hcl | Tramadol Hcl | 243 | 56 |
| Furosemide | Furosemide | 242 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 233 | 61 |
| Losartan Potassium | Losartan Potassium | 231 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 87 |
| Metformin Hcl | Metformin Hcl | 211 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 45 |
| Glipizide Er | Glipizide | 165 | 44 |
| Meloxicam | Meloxicam | 161 | 53 |
| Azithromycin | Azithromycin | 154 | 101 |
| Eliquis | Apixaban | 145 | 35 |
| Trazodone Hcl | Trazodone Hcl | 144 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 34 |
| Simvastatin | Simvastatin | 135 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 28 |
| Ozempic | Semaglutide | 117 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 42 |
| Metformin Hcl Er | Metformin Hcl | 111 | 35 |
| Ibuprofen | Ibuprofen | 99 | 33 |
| Alprazolam | Alprazolam | 97 | 11 |
| Ondansetron Odt | Ondansetron | 93 | 35 |
| Alendronate Sodium | Alendronate Sodium | 88 | 21 |
| Spironolactone | Spironolactone | 88 | 22 |
| Lovastatin | Lovastatin | 87 | 18 |
| Methylprednisolone | Methylprednisolone | 86 | 48 |
| Allopurinol | Allopurinol | 84 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 46 |
| Carvedilol | Carvedilol | 81 | 21 |
| Donepezil Hcl | Donepezil Hcl | 81 | 22 |
| Megestrol Acetate | Megestrol Acetate | 79 | 24 |
| Sertraline Hcl | Sertraline Hcl | 78 | 25 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 18 |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Atenolol | Atenolol | 65 | 16 |
| Diazepam | Diazepam | 65 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 15 |
| Valsartan | Valsartan | 62 | 17 |
| Finasteride | Finasteride | 60 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 42 |
| Xarelto | Rivaroxaban | 59 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 17 |
| Pregabalin | Pregabalin | 56 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 20 |
| Synthroid | Levothyroxine Sodium | 55 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 16 |
| Methocarbamol | Methocarbamol | 53 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 15 |
| Meclizine Hcl | Meclizine Hcl | 50 | 22 |
| Nifedipine Er | Nifedipine | 49 | 13 |
| Celecoxib | Celecoxib | 48 | 14 |
| Clonidine Hcl | Clonidine Hcl | 48 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 17 |
| Entresto | Sacubitril/Valsartan | 47 | 15 |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Lactulose | Lactulose | 47 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 20 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Mirtazapine | Mirtazapine | 47 | 12 |
| Nystatin | Nystatin | 47 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 14 |
| Fenofibrate | Fenofibrate | 45 | suppressed |
| Glimepiride | Glimepiride | 45 | 12 |
| Azelastine Hcl | Azelastine Hcl | 44 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Buspirone Hcl | Buspirone Hcl | 40 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 16 |
| Fluconazole | Fluconazole | 39 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Mupirocin | Mupirocin | 35 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Cefdinir | Cefdinir | 34 | 25 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 16 |
| Jardiance | Empagliflozin | 32 | 11 |
| Nitroglycerin | Nitroglycerin | 32 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 15 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 12 |
| Prednisone | Prednisone | 30 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 12 |
| Ibu | Ibuprofen | 27 | 13 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Glipizide | Glipizide | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 13 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Victoza 3-Pak | Liraglutide | 15 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $348.77 · 16 records | Kowa Pharmaceuticals America, Inc. | AIRSUPRA, AREXVY, Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 2, Kerendia, NURTEC ODT, SHINGRIX, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error